DL-2-(2-Chlorophenyl)glycine CAS 141196-64-7 Assay ≥98.5% High Purity Clopidogrel Intermediate
Supply with High Purity and Stable Quality
Chemical Name: DL-2-(2-Chlorophenyl)glycine
Synonyms: H-DL-Phg(2-Cl)-OH
CAS: 141196-64-7
High Quality, Commercial Production
Chemical Name | DL-2-(2-Chlorophenyl)glycine |
Synonyms | H-DL-Phg(2-Cl)-OH |
CAS Number | 141196-64-7 |
CAT Number | RF-CC254 |
Stock Status | In Stock |
Molecular Formula | C8H8ClNO2 |
Molecular Weight | 185.61 |
Refractive Index | 1.603 |
Density | 1.392g/cm3 |
Shipping Condition | Shipped Under Ambient Temperature |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White to Off-White Powder |
Loss on Drying | ≤1.0% |
Melting Point | 195.0~203.0℃ |
Chlorides | ≤1000mg/kg |
Acid Solubility Test | Qualified |
Assay | ≥98.5% |
Test Standard | Enterprise Standard |
Usage | Clopidogrel Intermediate; Pharmaceutical Intermediate |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of DL-2-(2-Chlorophenyl)glycine (CAS: 141196-64-7) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and active pharmaceutical ingredient (API) synthesis.
DL-2-(2-Chlorophenyl)glycine (CAS: 141196-64-7) is an intermediate typically in the synthesis of Clopidogrel (CAS: 113665-84-2), API.
Clopidogrel was launched in the US as a potent inhibitor of platelet aggregation for the preventive management of secondary ischemic events, including MI, stroke and vascular deaths. Clopidogrel can be synthesized in 4 steps (including an optical resolution to the S active enantiomer) from DL-2-(2-Chlorophenyl)glycine (CAS: 141196-64-7), the key step being the cyclization to thienopyridine with formaldehyde and acetic acid. Unlike other thienopyridinescurrently used, clopidogrel does not seriously reduce thenumber of white cells in the blood, and therefore, routinemonitoring of the white blood cell count is not necessaryduring treatment.